New drug trial aims to better control aggressive blood cancer
NCT ID NCT07033598
Summary
This study is testing whether a newer drug called pacritinib works better than the standard drug hydroxyurea for adults with an advanced, fast-growing type of blood cancer called chronic myelomonocytic leukemia. About 66 participants will be randomly assigned to take one of the two drugs for up to 48 weeks. Researchers will compare which drug is more effective at controlling the disease and has fewer side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOMONOCYTIC, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Email: •••••@•••••
-
Mayo Clinic Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-••••
Contact
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact Email: •••••@•••••
Contact
-
Winship Cancer Institute at Emory
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.